FDA PMA FDA Class 3 Approved 🇺🇸 United States

Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

PMA: P910007 · Supplement: S010 · Decision Apr 28, 2004
Classifications
1
FEI Numbers
15
Registration Numbers
15

Basic Information

Device Name
Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer
Trade Name
ABBOTT ARCHITECT TOTAL PSA ASSAY
PMA Number
P910007
Supplement Number
S010
Device Class
FDA Class 3
Product Code
MTF
Generic Name
Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer
Medical Specialty
Unknown
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
April 28, 2004
Date Received
April 1, 2004
Supplement Type
Real-Time Process
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR THE ABBOTT ARCHITECT TOTAL PSA ASSAY TO BE USED ON THE ARCHITECT I2000SR PLATFORM, A MEMBER OF THE ARCHITECT I2000 INSTRUMENT FAMILY. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE SAME TRADE NAME ARCHITECT TOTAL PSA ASSAY AND IS INDICATED: THE ARCHITECT TOTAL PSA ASSAY IS A CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (CMIA) FOR THE QUANTITATIVE DETERMINATION OF TOTAL PSA (BOTH FREE PSA AND PSA COMPLEXED TO ALPHA-1-ANTICHYMOTRYPSIN [PSA-ACT]) IN HUMAN SERUM: 1) AS AN AID IN THE DETECTION OF PROSTATE CANCER WHEN USED IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) IN MEN 50 YEARS OR OLDER. PROSTATIC BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. 2) AS AN ADJUNCTIVE TEST TO AID IN THE MANAGEMENT OF PROSTATE CANCER PATIENTS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MTF Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer